Liquid Biopsy Market Projected To Grow High Due To Highly Invasive Nature Of Traditional Biopsies Till 2030: Grand View Research Inc.

March 07 14:48 2019

Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research, Enhanced view of tumor provided by liquid biopsy technology is estimated to augment the market in coming years. While tissue biopsies have been standard for cancer diagnosis for past several year, their highly invasive nature and frequently associated complications have been major concerns.

According to a report,“Liquid Biopsy Market Size, Share & Trends Analysis Report By Application, By Sample Type (Blood, Urine) By Biomarker Type (CTC, ctDNA, Exosomes), By Technology (NGS, PCR), By Region, And Segment Forecasts, 2018 – 2030”, published by Grand View Research, Inc., the global liquid biopsy market size is expected to reach USD 5.96 billion by 2030, exhibiting a CAGR of 13.4% during the forecast period. Enhanced view of tumor provided by liquid biopsy technology is estimated to augment the market in coming years.

Key Takeaways from the report:

  • Technological developments such as electric field induced release and measurement (EFIRM)- Liquid Biopsy (eLB), which provides detection that can assist clinical treatment decisions for most common subtype of cancers are expected to drive the uptake of saliva based sampling over the forecast period

  • Currently, clinical use of isolation and detection technology is limited to CTC quantitation but the number of CTCs is found to hold significant correlation with disease severity. This is, thus, estimated to augment the market over the coming years

  • Rising awareness regarding advantages of multiple gene analysis along with the help of NGS is anticipated to support the growth of the market

  • Organizations such as American Society of Clinical Oncology (ASCO) are engaged in supporting implementation of liquid biopsy, which in turn is likely to spur the growth of the market

  • Intensifying competition between biotech companies and increasing investments by government in healthcare institutes will lead to development of more sophisticated tests

  • Companies engaged in R&D and commercialization of these products include Pathway Genomics; Natera Inc.; Epic Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom

U.S. Liquid Biopsy Market Size, by Application, 2013 - 2030, (USD Million)

Browse More Reports in Biotechnology Industry:

  • Cancer Immunotherapy Drug Discovery Outsourcing Market: Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the Cancer Immunotherapy Drug Discovery Outsourcing market.
  • Biomaterials Market: Technological innovations in the field of biomaterials are leading to development of advanced products, which in turn is working in favor of the market. 

Global Liquid Biopsy Market Share, by Region, 2016 (%)

While tissue biopsies have been standard for cancer diagnosis for past several year, their highly invasive nature and frequently associated complications have been major concerns. Moreover, these biopsies lead to high expenditure being incurred by patients. Liquid biopsies, on the other hand, offer a less invasive methodology along with high effectiveness. Thus, there are a number of key private organizations involved in rigorous R&D activities for liquid biopsy test development and it is only a matter of time before these procedures grow in prominence in diagnostic paraphernalia of oncologists and pathologists.

Grand View Research has segmented the global liquid biopsy marketon the basis of application, sample type, biomarker, technology, and region:

Liquid Biopsy Application Outlook (Revenue, USD Million, 2013 – 2030)

  • Therapy Selection for Metastatic Breast Cancer (MBS)

  • Therapy Selection for Other Metastatic Cancer

  • Molecular Health Monitoring

Liquid Biopsy Sample Type Outlook (Revenue, USD Million, 2013 – 2030)

  • Blood Sample based

  • Urine Sample based

  • Other Bio Fluids (Tissue fluids and Saliva) based

Liquid Biopsy Biomarker Outlook (Revenue, USD Million, 2013 – 2030)

  • Circulating Tumor Cells (CTC)

  • Circulating Tumor DNA (ctDNA)

  • Exosomes

Liquid Biopsy Technology Outlook (Revenue, USD Million, 2013 – 2030)

  • Multi-gene-parallel Analysis (NGS)

  • Single Gene Analysis (PCR Microarrays)

Liquid Biopsy Regional Outlook (Revenue, USD Million, 2013 – 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

  • MEA

    • South Africa

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

For more information: www.grandviewresearch.com

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: Switzerland
Website: www.grandviewresearch.com/industry-analysis/liquid-biopsy-market